UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abidin, A. (2025). *Profil Ekspresi Plasma Circulating miRNA sebagai Kandidat Biomarker Prediktor Metastasis Tulang pada Pasien Kanker Payudara HR+/HER2-*. Universitas Gadjah Mada.

Abou Madawi, N. A., Darwish, Z. E., & Omar, E. M. (2024). Targeted gene therapy for cancer: the impact of microRNA multipotentiality. *Medical Oncology*, *41*(9), 1–14. https://doi.org/10.1007/s12032-024-02450-1

AboZaid, O. A. R., Abdel-Maksoud, M. A., Saleh, I. A., El-Tayeb, M. A., EL-sonbaty, S. M., Shoker, F. E., Salem, M. A., Emad, A. M., Mani, S., Deva Magendhra Rao, A. K., Mamdouh, M. A., Kotob, M. H., Aufy, M., & Kodous, A. S. (2024). Targeting the NF-κB p65/Bcl-2 signaling pathway in hepatic cellular carcinoma using radiation assisted synthesis of zinc nanoparticles coated with naturally isolated gallic acid. *Biomedicine and Pharmacotherapy*, *172*(February), 116274. https://doi.org/10.1016/j.biopha.2024.116274

Akoglu, H. (2018). User's guide to correlation coefficients. *Turkish Journal of Emergency Medicine*, *18*(3), 91–93. https://doi.org/10.1016/j.tjem.2018.08.001

Alamukii, N. A., Kovács, A., Raghavan, S., Ilio, J., Karlsson, P., Helou, K., & Parris, T. Z. (2025). Immune-stromal heterogeneity in breast cancer across diverse ancestries: impact on prognosis and treatment response. *Npj Breast Cancer*, *11*(1). https://doi.org/10.1038/s41523-025-00881-1

American Joint Committee On Cancer. (2012). AJCC Cancer Staging Manual : Seventh Edition. In *Radiology Illustrated: Uroradiology (Second Edition)* (Vol. 9783642053).

Anonim. (1975). NanoDrop Spectrophotometers: 260/280 and 260/230 Ratios. *Technical Bulletin Thermo Scientific*, 2–3.

Anonim. (2025). *TNM Staging for Breast Cancer*. National Cancer Institute. https://www.cancer.gov/types/breast/stages/tnm-staging-system

Bediaga, N. G., Beristain, E., Calvo, B., Viguri, M. A., Gutierrez-Corres, B., Rezola, R., Ruiz-Diaz, I., Guerra, I., & de Pancorbo, M. M. (2016). Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. *SpringerPlus*, *5*(1). https://doi.org/10.1186/s40064-016-2235-0

Bratton, M. R. ., Duong, B. N. ., Elliott, S., Weldon, C. B. ., Beckman, B. S. ., Mclachlan, J. A. ., & Burow, M. E. (2010). Regulation of ERα-mediated of Bcl-2 by P13K-AKT crosstalk: Implikation for breast cancer survival. *Int J Oncol.*, *37*(3), 541–550. https://doi.org/https://doi.org/10.3892/ijo_00000703

Cancer Registry. (2023). *RKBR Desember 2023: Tren Kanker Tahun 2008-2021*. FK-KMK UGM. https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-desember-2023/

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Carvalho, E., Canberk, S., Schmitt, F., & Vale, N. (2025). Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. *Cancers*, *17*(7). https://doi.org/10.3390/cancers17071102

Catalanotto, C., Cogoni, C., & Zardo, G. (2016). MicroRNA in control of gene expression: An overview of nuclear functions. *International Journal of Molecular Sciences*, *17*(10). https://doi.org/10.3390/ijms17101712

Catz, S. D., & Johnson, J. L. (2001). Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. *Oncogene*, *20*(50), 7342–7351. https://doi.org/10.1038/sj.onc.1204926

Chen, B. F., Tsai, Y. F., Huang, C. C., Hsu, C. Y., Lien, P. J., Wang, Y. L., Lin, Y. S., Feng, C. J., King, K. L., Chiu, J. H., Chau, G. Y., & Tseng, L. M. (2022). Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan. *Journal of the Chinese Medical Association*, *85*(2), 190–197. https://doi.org/10.1097/JCMA.0000000000000632

Chu, M., Fan, Y., Wu, L., Ma, X., Sao, J., Yao, Y., Zhuang, W., & Zhang, C. (2022). Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2 axis. *Immunity and Ageing*, *19*(1), 1–17. https://doi.org/10.1186/s12979-021-00258-5

Creighton, C. J. (2012a). The molecular profile of luminal B breast cancer. *Biologics: Targets and Therapy*, *6*, 289–297. https://doi.org/10.2147/BTT.S29923

Creighton, C. J. (2012b). The molecular profile of luminal B breast cancer. *Biologics: Targets and Therapy*, *6*, 289–297. https://doi.org/10.2147/BTT.S29923

Croce, C. M., Tait, S. W. G., Garcia-Sáez, A. J., Villunger, A., Letai, A., Walter, H. S., Dyer, M. J. S., Green, D. R., Shi, Y., & Melino, G. (2026). What does BCL-2 do? From new molecular insights to the clinical implications. *Cell Death and Differentiation*, *July 2025*. https://doi.org/10.1038/s41418-025-01607-3

Denkert, C., Rachakonda, S., Karn, T., Weber, K., Martin, M., Marmé, F., Untch, M., Bonnefoi, H., Kim, S. B., Seiler, S., Bear, H. D., Witkiewicz, A. K., Im, S. A., DeMichele, A., Pehl, A., van't Veer, L., McCarthy, N., Stiewe, T., Jank, P., … Loibl, S. (2025). Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping. *Cancer Cell*, *43*(2), 232-247.e4. https://doi.org/10.1016/j.ccell.2025.01.002

Diener, C., Keller, A., & Meese, E. (2022). Emerging concepts of miRNA therapeutics: from cells to clinic. *Trends in Genetics*, *38*(6), 613–626. https://doi.org/10.1016/j.tig.2022.02.006

Duan, L., Tao, J., Yang, X., Ye, L., Wu, Y., He, Q., Duan, Y., Chen, L., & Zhu, J. (2020). HVEM/HIF-1α promoted proliferation and inhibited apoptosis of

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

ovarian cancer cells under hypoxic microenvironment conditions. *Journal of Ovarian Research*, *13*(1), 1–11. https://doi.org/10.1186/s13048-020-00646-3

Elango, R., Alsaleh, K. A., Vishnubalaji, R., Manikandan, M., Ali, A. M., Abd El-Aziz, N., Altheyab, A., Al-Rikabi, A., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2020). MicroRNA Expression Profiling on Paired Primary and Lymph Node Metastatic Breast Cancer Revealed Distinct microRNA Profile Associated With LNM. *Frontiers in Oncology*, *10*(May), 1–13. https://doi.org/10.3389/fonc.2020.00756

Eom, Y. H., Kim, H. S., Lee, A., Song, B. J., & Chae, B. J. (2016). BCL2 as a subtype-specific prognostic marker for breast cancer. *Journal of Breast Cancer*, *19*(3), 252–260. https://doi.org/10.4048/jbc.2016.19.3.252

Galvão-Lima, L. J., Morais, A. H. F., Valentim, R. A. M., & Barreto, E. J. S. S. (2021). miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. *BioMedical Engineering Online*, *20*(1), 1–20. https://doi.org/10.1186/s12938-021-00857-9

Ghoshal-Gupta, S., Kutiyanawalla, A., Lee, B. R., Ojha, J., Nurani, A., Mondal, A. K., Kolhe, R., Rojiani, A. M., & Rojiani, M. V. (2018). TIMP-1 downregulation modulates miR-125a-5p expression and triggers the apoptotic pathway. *Oncotarget*, *9*(10), 8941–8956. https://doi.org/10.18632/oncotarget.23832

Gugnoni, M., Kashyap, M. K., Wary, K. K., & Ciarrocchi, A. (2025). lncRNAs: the unexpected link between protein synthesis and cancer adaptation. *Molecular Cancer*, *24*(1). https://doi.org/10.1186/s12943-025-02236-7

Hassan, Z. M., Mamand, D. R., El-Gawly, H. W., El-Sherbeeny, N. A., Mohammad, H. M. F., Elkherbetawy, M. K., Wiklander, O. P. B., & Hassan, M. (2026). Differential Modulation of JAK/STAT3 Signaling and BCL-2 Family Proteins by Tetracycline Analogues in Leukemia Models. *Pharmaceutics*, *18*(4), 1–16. https://doi.org/10.3390/pharmaceutics18040415

He, H., Xu, F., Huang, W., Luo, S. Y., Lin, Y. T., Zhang, G. H., Du, Q., & Duan, R. H. (2015). miR-125a-5p expression is associated with the age of breast cancer patients. *Genetics and Molecular Research*, *14*(4), 17927–17933. https://doi.org/10.4238/2015.December.22.17

Höller, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023). Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now? *Breast Cancer: Targets and Therapy*, *15*, 525–540. https://doi.org/10.2147/BCTT.S340741

Honma, N., Horii, R., Ito, Y., Saji, S., Younes, M., Iwase, T., & Akiyama, F. (2015). Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. *BMC Cancer*, *15*(1). https://doi.org/10.1186/s12885-015-1686-y

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Hsieh, T. H., Hsu, C. Y., Tsai, C. F., Long, C. Y., Wu, C. H., Wu, D. C., Lee, J. N., Chang, W. C., & Tsai, E. M. (2015). HDAC inhibitors target HDAC5, upregulate MicroRNA-125a-5p, and induce apoptosis in breast cancer cells. *Molecular Therapy*, *23*(4), 656–666. https://doi.org/10.1038/mt.2014.247

Huang, X., Zhang, Q., & Wang, N. (2021). The significance of Bcl-2 expression in breast cancer: A 10- year follow-up study. *Journal of Clinical Investigation and Studies*, *4*(1), 1–6. https://doi.org/10.15761/jcis.1000127

Julia Y.S. Tsang, Gary, M. T. (2020). Molecular classification of breast cancer. *Breast Cancer Essentials: Perspectives for Surgeons*, *27*(1), 33–38. https://doi.org/10.1007/978-3-030-73147-2_4

Kawiak, A., & Kostecka, A. (2022). Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. *Cancers*, *14*(2). https://doi.org/10.3390/cancers14020279

Kretzmann, H. G., & Adeniyi, O. V. (2025). Clinicopathological and molecular subtypes of breast cancer in the Eastern Cape, South Africa: A two-year retrospective study. *Plos One*, *20*(7 July), 1–16. https://doi.org/10.1371/journal.pone.0325387

Kuschner, O'connor, & Butz, A. M. (2017). Structural and Functional Characterization of Aromatase, Estrogen Receptor, and Their Genes in Endocrine-Responsive and – Resistant Breast Cancer Cells. *Physiology & Behavior*, *176*(12), 139–148. https://doi.org/10.1016/j.jsbmb.2015.07.018.Structural

Labi, V., & Erlacher, M. (2015). How cell death shapes cancer. *Cell Death and Disease*, *6*(3), 1–11. https://doi.org/10.1038/cddis.2015.20

LI, D., CHEN, L., ZHANG, X., WANG, Y., HUANG, C., LI, J., HE, F., & HE, W. (2021). miR-125a-5p reverses epithelial-mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer. *Molecular Medicine Reports*, *24*(5), 1–11. https://doi.org/10.3892/mmr.2021.12452

Liang, Z., Pan, Q., Zhang, Z., Huang, C., Yan, Z., Zhang, Y., & Li, J. (2019). MicroRNA-125a-5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF-7 breast cancer cells. In *Molecular Medicine Reports* (Vol. 20, Issue 5, pp. 4507–4514). https://doi.org/10.3892/mmr.2019.10704

Lin, S., & Gregory, R. I. (2015). MicroRNA biogenesis pathways in cancer. *Nature Reviews Cancer*, *15*(6), 321–333. https://doi.org/10.1038/nrc3932

Lv, J., Ren, J., Zheng, J., Zhang, F., & Han, M. (2022). Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer. *Disease Markers*, *2022*. https://doi.org/10.1155/2022/5621441

Manjunath, G. K., Nashier, D., & Kumar, A. (2026). Transcriptional and Pathway

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Level Heterogeneity in Luminal A Breast Cancer: A Framework for Precision Therapy. *Archives of Medical Research*, *57*(3), 103384. https://doi.org/10.1016/j.arcmed.2026.103384

Marie Hardwick, J., & Soane, L. (2013). Multiple functions of BCL-2 family proteins. *Cold Spring Harbor Perspectives in Biology*, *5*(2), 1–22. https://doi.org/10.1101/cshperspect.a008722

Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L. L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., Gingeras, T. R., Guttman, M., Hirose, T., Huarte, M., Johnson, R., Kanduri, C., Kapranov, P., Lawrence, J. B., Lee, J. T., … Wu, M. (2023). Long non-coding RNAs: definitions, functions, challenges and recommendations. *Nature Reviews Molecular Cell Biology*, *24*(6), 430–447. https://doi.org/10.1038/s41580-022-00566-8

Mayrovitz, H. N. (2022). Breast Cancer. In *Breast Cancer*. https://doi.org/10.36255/exon-publications-breast-cancer

Morana, O., Wood, W., & Gregory, C. D. (2022). The Apoptosis Paradox in Cancer. *International Journal of Molecular Sciences*, *23*(3). https://doi.org/10.3390/ijms23031328

Moukettei, B. ., Barupala, N. ., Aonuma, T. ., Sepulveda, M. ., Kawaguchi, S., & Kim, I. (2021). Interactions between noncoding RNAs as epigenetic regulatory mechanisms in cardiovascular diseases. *Methods in Cell Biology*, *166*, 306–312.

Nehra, R., Riggins, R. B., Shajahan, A. N., Zwart, A., Crawford, A. C., & Clarke, R. (2010). BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. *The FASEB Journal*, *24*(6), 2040–2055. https://doi.org/10.1096/fj.09-138305

Nicolini, A., Ferrari, P., Silvestri, R., & Gemignani, F. (2024). The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy. *Journal of the National Cancer Center*, *4*(1), 14–24. https://doi.org/10.1016/j.jncc.2024.01.004

Ning, Z., Yu, S., Zhao, Y., Wang, Y., Fan, Q., Song, T., & Yu, X. (2020). Survival Marker miRNA-Mediated Subpathways of Breast Invasive Carcinoma Derived from Activity Profile. *IEEE Access*, *8*, 160947–160956. https://doi.org/10.1109/ACCESS.2020.3018148

O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology*, *9*(AUG), 1–12. https://doi.org/10.3389/fendo.2018.00402

Pandey, S., & Yadav, P. (2025). Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy. *Journal of Genetic Engineering and Biotechnology*, *23*(4), 100556.

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

https://doi.org/10.1016/j.jgeb.2025.100556

Polyak, K. (2011). Review series introduction Heterogeneity in breast cancer. *J.Clin.Invest.*, *121*(10), 2011–2013. https://doi.org/10.1172/JCI60534.3786

Poudel, P., Nyamundanda, G., Patil, Y., Cheang, M. C. U., & Sadanandam, A. (2019). Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. *Npj Breast Cancer*, *5*(1), 1–10. https://doi.org/10.1038/s41523-019-0116-8

Prize, T. N. (2024). What will it take to get miRNA therapies to market? *Nature Biotechnology*, *42*(11), 1623–1624. https://doi.org/10.1038/s41587-024-02480-0

Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022). The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. *Frontiers in Oncology*, *12*(October), 1–16. https://doi.org/10.3389/fonc.2022.985363

Richard, V., Nair, M. G., Jaikumar, V. S., Jones, S., Prabhu, J. S., & Kerin, M. J. (2023). Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators. *International Journal of Molecular Sciences*, *24*(4). https://doi.org/10.3390/ijms24043497

Sepúlveda, P., Encabo, A., Carbonell-Uberos, F., & Miñana, M. D. (2007). BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. *Cell Death and Differentiation*, *14*(2), 378–380. https://doi.org/10.1038/sj.cdd.4402007

Seyhan, A. A. (2024). Trials and Tribulations of MicroRNA Therapeutics. *International Journal of Molecular Sciences*, *25*(3), 1–41. https://doi.org/10.3390/ijms25031469

Sharma, S., Patnaik, P. K., Aronov, S., & Kulshreshtha, R. (2016). ApoptomiRs of breast cancer: Basics to clinics. In *Frontiers in Genetics* (Vol. 7, Issue SEP). https://doi.org/10.3389/fgene.2016.00175

Silva, J. P. N., Pinto, B., Silva, P. M. A., & Bousbaa, H. (2026). BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. *International Journal of Molecular Sciences*, *27*(2), 1–59. https://doi.org/10.3390/ijms27021123

Smolarz, B., Zadrożna Nowak, A., & Romanowicz, H. (2022). Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers*, *14*(10), 1–27. https://doi.org/10.3390/cancers14102569

Somal, P. K., Sancheti, S., Sharma, A., Sali, A. P., Chaudhary, D., Goel, A., Dora, T. K., Brar, R., Gulia, A., & Divatia, J. (2023). A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India. *South Asian Journal of Cancer*, *12*(2), 104–111. https://doi.org/10.1055/s-0043-1761942

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Statello, L., Guo, C. J., Chen, L. L., & Huarte, M. (2021). Gene regulation by long non-coding RNAs and its biological functions. *Nature Reviews Molecular Cell Biology*, *22*(2), 96–118. https://doi.org/10.1038/s41580-020-00315-9

Subhaktiyasa, P. G. (2024). Menentukan Populasi dan Sampel : Pendekatan Metodologi Penelitian Kuantitatif dan Kualitatif. *Jurnal Ilmiah Profesi Pendidikan*, *9*(4), 2721–2731. https://doi.org/https://doi.org/10.29303/jipp.v9i4.2657

Syeda, Z. A., Langden, S. S. S., Munkhzul, C., Lee, M., & Song, S. J. (2020). Regulatory mechanism of microrna expression in cancer. *International Journal of Molecular Sciences*, *21*(5). https://doi.org/10.3390/ijms21051723

Tong, Z., Liu, N., Lin, L., Guo, X., Yang, D., & Zhang, Q. (2015). miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. *Biomedicine and Pharmacotherapy*, *75*, 129–136. https://doi.org/10.1016/j.biopha.2015.07.036

Turkoglu, F., Calisir, A., & Ozturk, B. (2024). Clinical importance of serum miRNA levels in breast cancer patients. *Discover Oncology*, *15*(1). https://doi.org/10.1007/s12672-024-00871-y

Vo, D. T., Karanam, N. K., Ding, L., Saha, D., Yordy, J. S., Giri, U., Heymach, J. V., & Story, M. D. (2019). miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer. *Neoplasia (United States)*, *21*(9), 849–862. https://doi.org/10.1016/j.neo.2019.06.004

Wahidin, M., Febrianti, R., Susanty, F., & Hasanah, S. R. (2022). Twelve Years Implementation of Cervical and Breast Cancer Screening Program in Indonesia. *Asian Pacific Journal of Cancer Prevention*, *23*(3), 829–837. https://doi.org/10.31557/APJCP.2022.23.3.829

Wang, F., Zu, Y., Zhu, S., Yang, Y., Huang, W., Xie, H., & Li, G. (2018). Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. *Biochemical and Biophysical Research Communications*, *507*(1–4), 231–235. https://doi.org/10.1016/j.bbrc.2018.11.013

Wang, L. B., Feng, L., He, J., Liu, B., & Sun, J. G. (2019). MiR-125a-5p inhibits the proliferation and invasion of breast cancer cells and induces apoptosis by targeting GAB2. *Mathematical Biosciences and Engineering*, *16*(6), 6923–6933. https://doi.org/10.3934/mbe.2019347

World Health Organization. (2022). *Estimated number of new cases from 2022 to 2050, Females, age [20-85+]*. Global Cancer Observatory. https://gco.iarc.who.int/tomorrow/en/dataviz/trends?multiple_populations=1&types=0&sexes=2&cancers=20&age_start=4

Xu, M., Zhan, J., Xie, J., Zhu, L., Chen, L., Luo, X., Sheng, X., Liu, T., Zhang, S.,

UNIVERSITAS
GADJAH MADA
Potensi Regulasi miR-125a-5p terhadap Ekspresi BCL2 Pasien Kanker Payudara HR+/HER2-
Putri Rohmatul Laili, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D.; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

& Lu, Z. (2021). MiR-125a-5p inhibits cell proliferation, cell cycle progression, and migration while promoting apoptosis in head and neck cancers by targeting ERBB3. *Auris Nasus Larynx*, *48*(3), 477–486. https://doi.org/10.1016/j.anl.2020.10.001

Xu, P., Li, X., Liang, Y., Bao, Z., Zhang, F., Gu, L., Kosari, S., & Liu, W. (2022). PmiRtarbase: A positive miRNA-target regulations database. *Computational Biology and Chemistry*, *98*, 107690. https://doi.org/10.1016/j.compbiolchem.2022.107690

Yan, L., Yu, M. C., Gao, G. L., Liang, H. W., Zhou, X. Y., Zhu, Z. T., Zhang, C. Y., Wang, Y. B., & Chen, X. (2018). MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. In *Journal of Cellular Biochemistry* (Vol. 119, Issue 11, pp. 8773–8783). https://doi.org/10.1002/jcb.27124

Yang, F., Shi, L., Liang, T., Ji, L., Zhang, G., Shen, Y., Zhu, F., & Xu, L. (2017). Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. *Biochemical and Biophysical Research Communications*, *485*(1), 54–61. https://doi.org/10.1016/j.bbrc.2017.02.017

Yang, J. L., Hodara, E., Sriprasert, I., Shoupe, D., & Stanczyk, F. Z. (2024). Estrogen deficiency in the menopause and the role of hormone therapy: Integrating the findings of basic science research with clinical trials. *Menopause*, *31*(10), 926–939. https://doi.org/10.1097/GME.0000000000002407

Yumeen, S., Mirza, F. N., Lewis, J. M., King, A. L. O., Kim, S. R., Carlson, K. R., Umlauf, S. R., Surovtseva, Y. V., Foss, F. M., & Girardi, M. (2020). JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. *Blood Advances*, *4*(10), 2213–2226. https://doi.org/10.1182/bloodadvances.2020001756

Zhang, X., Wang, W., Zhu, W., Dong, J., Cheng, Y., Yin, Z., & Shen, F. (2019). Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. *International Journal of Molecular Sciences*.

Zheng, L., Meng, X., Li, X., Zhang, Y., Li, C., Xiang, C., Xing, Y., Xia, Y., & Xi, T. (2018). MIR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. *FASEB Journal*, *32*(2), 588–600. https://doi.org/10.1096/fj.201700461RR